author-photo

Takeshi Ueda

University of Duisburg-Essen

5

Papers

3728

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]

2018 European Urology
Show All
- Source
- Cite
- Save
Citations (5)
CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (30)
CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)

2015 BJUI
Show All
- Source
- Cite
- Save
Citations (15)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

2015 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (3543)